Prospective assessment of short-term propylene glycol tolerance in neonates

被引:40
作者
Allegaert, Karel [1 ]
Vanhaesebrouck, Sophie
Kulo, Aida [2 ,3 ]
Cosaert, Katrien [4 ]
Verbesselt, Rene [2 ]
Debeer, Anne
de Hoon, Jan [2 ]
机构
[1] Univ Hosp Leuven, Div Woman & Child, Neonatal Intens Care Unit, B-3000 Louvain, Belgium
[2] Univ Hosp Leuven, Ctr Clin Pharmacol, B-3000 Louvain, Belgium
[3] Univ Sarajevo, Fac Med, Inst Pharmacol Clin Pharmacol & Toxicol, Sarajevo 71000, Bosnia & Herceg
[4] Univ Hosp Leuven, Hosp Pharm, B-3000 Louvain, Belgium
关键词
PARACETAMOL; TOXICITY; PHARMACOKINETICS; PROPACETAMOL; POPULATION; INFUSION; CHILDREN; DRUG;
D O I
10.1136/adc.2010.190330
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction Propylene glycol (PG) is an unintentional frequently administered solvent in neonates despite the fact that PG accumulation potentially results in hyperosmolarity, lactic acidosis and renal/hepatic toxicity. Methods Prospective evaluation of renal (diuresis, creatinaemia, sodium), metabolic (base excess, anion gap, lactate, bicarbonate) and hepatic (alanine transaminase, aspartate aminotransferase, direct bilirubinaemia) tolerance to PG in (pre)term neonates following intravenous administration of formulations (paracetamol, phenobarbital, digoxin) that contain PG. Observations from 48 h before up to 48 after the last PG administration were described and compared (paired analysis). Clinical characteristics and observations collected following intravenous PG-paracetamol administration were compared with a historical cohort of neonates in whom similar (renal, hepatic) observations during exposure to a mannitol-containing paracetamol formulation were collected. Results 5566 observations were collected in 69 neonates before, during and following median PG exposure of 34 mg/kg/24 h (range 14-252). Progressive postnatal adaptation in renal, metabolic and hepatic function was documented, unrelated to the PG exposure. In the subgroup of 40 cases treated with intravenous PG-paracetamol, observations on renal and hepatic function were similar to a historical cohort of published observations following exposure to intravenous mannitol-paracetamol. Conclusions Unintended PG administration (34 mg/kg/24 h) for a maximum of 48 h seems to be tolerated in (pre)term neonates and does not affect short-term postnatal adaptations. Further studies on PG disposition and the level of safe exposure to PG, including long-term safety data in neonates are needed.
引用
收藏
页码:1054 / 1058
页数:5
相关论文
共 22 条
[1]   Intra- and interindividual variability of glucuronidation of paracetamol during repeated administration of propacetamol in neonates [J].
Allegaert, K ;
De Hoon, J ;
Verbesselt, R ;
Vanhole, C ;
Devlieger, H ;
Tibboel, D .
ACTA PAEDIATRICA, 2005, 94 (09) :1273-1279
[2]   Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates [J].
Allegaert, K ;
Anderson, BJ ;
Naulaers, G ;
de Hoon, J ;
Verbesselt, R ;
Debeer, A ;
Devlieger, H ;
Tibboel, D .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (03) :191-197
[3]  
Allegaert K, 2009, Verh K Acad Geneeskd Belg, V71, P141
[4]  
Allegaert K, 2008, PEDIATR ANESTH, V18, P388, DOI 10.1111/j.1460-9592.2008.02535.x
[5]   Population clinical pharmacology of children: modelling covariate effects [J].
Anderson, Brian J. ;
Allegaert, Karel ;
Holford, Nicholas H. G. .
EUROPEAN JOURNAL OF PEDIATRICS, 2006, 165 (12) :819-829
[6]  
[Anonymous], 1997, Pediatrics, V99, P268
[7]   Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients [J].
Chicella, M ;
Jansen, P ;
Parthiban, A ;
Marlowe, KF ;
Bencsath, FA ;
Krueger, KP ;
Boerth, R .
CRITICAL CARE MEDICINE, 2002, 30 (12) :2752-2756
[8]  
GLASGOW AM, 1983, PEDIATRICS, V72, P353
[9]   An overview of children as a special population - Relevance to predictive biomarkers [J].
Kimmel, GL .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2005, 206 (02) :215-218
[10]   Novel methods for the detection of drug and alcohol exposure during pregnancy: Implications for maternal and child health [J].
Koren, G. ;
Hutson, J. ;
Gareri, J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (04) :631-634